Allurar rigakafi ta kashi
Allurar rigakafi ta kashi |
---|
allurar rigakafi kashi [1] wata dabara ce don rage yawan allurar rigakafi kuma an cimma burin manufofin allurar wanda ya fi wuya a cimma tare da hanyoyin allurar rigakafi na al'ada, [2] isa ga mutane da yawa a cikin saitin iyakantaccen kasafin kuɗi na kiwon lafiya, ko rage tasirin illa saboda allurar rigapa.[3]
Allurar rigakafi ta raguwa tana amfani da halaye masu amsawa na allurar rigakafin: Idan za a iya yin allurar rigakawa ga mutane biyu maimakon ɗaya, amma kowannensu yana samun 2/3 na ingancin kariya, akwai fa'ida a sikelin al'umma don rage yawan kamuwa da cuta. Idan kasafin kudin kiwon lafiya yana da iyaka ko kuma kawai an sami iyakacin allurar rigakafi a farkon lokacin annobar, wannan na iya haifar da bambanci ga jimlar adadin kamuwa da cuta. [ana buƙatar hujja][
Allurar rigakafin kashi-kashi tana amfani da kashi na daidaitattun allurar rigakafi na yau da kullun wanda ake gudanar da shi ta wannan hanyar, ko kuma wata hanya ta daban (sau da yawa a karkashin fata ko intradermally). [4]
An yi amfani da allurar rigakafi ko kuma an ba da shawarar a cikin cututtukan talauci masu yaduwa da suka hada da zazzabin cizon sauro, [2] COVID-19. [5][6]
Amfani da shi
[gyara sashe | gyara masomin]A cikin mahallin iyakantaccen kasafin kuɗi na kiwon lafiya
[gyara sashe | gyara masomin]A lokacin barkewar zazzabin rawaya na 2016 a Angola da Jamhuriyar Demokradiyyar Kongo, WHO ta amince da amfani da allurar rigakafi don magance yiwuwar karancin allurar rigakawa.[7] A watan Agustan 2016, babban kamfen na allurar rigakafi a Kinshasa ya yi amfani da 1/5 na daidaitattun allurar rigakawa.[8] A cikin 2018 an ba da rahoton cewa allurar rigakafi ta raguwa tare da 1/5 na daidaitattun allurar rigakawa, wanda aka gudanar a cikin ciki, ya ba da kariya na shekaru 10, kamar yadda aka rubuta ta hanyar gwajin asibiti.[9]
A cikin Poliomyelitis, an nuna allurar rigakafin kashi ɗaya yana da tasiri yayin rage farashin gaba ɗaya, yana ba da allurar rigakawa ta Cutar shan inna ga wasu mutane.[10]
A cikin annobar COVID-19
[gyara sashe | gyara masomin]A cikin yaduwar annoba, ana ɗaukar allurar rigakafi ta raguwa don hanzarta samun damar yin allurar rigakawa lokacin da aka iyakance allurar riguna:
A cikin annoba COVID-19, samfuran cututtukan cututtuka suna hango babban fa'idar dabarun allurar rigakafin da aka tsara tare da wasu allurar rigakawa dangane da nauyin shari'a, mutuwar, da gajarta cutar.[3][11]
Don rage tasirin illa
[gyara sashe | gyara masomin]A wasu sassan yawan jama'a, haɗarin kamuwa da cuta ya fi ƙanƙanta amma ƙarancin haɗarin tasirin allurar rigakafi na iya ƙaruwa.[12] A cikin irin waɗannan ƙananan jama'a, allurar rigakafi na raguwa na iya inganta yawan haɗarin rigakafi ga mutum kuma inganta dangantakar farashi da fa'ida ga al'umma. [ana buƙatar hujja][<span title="This claim needs references to reliable sources. (March 2022)">citation needed</span>]
Manazarta
[gyara sashe | gyara masomin]- ↑ Chen, Zhimin; Liu, Kaihui; Liu, Xiuxiang; Lou, Yijun (2020-02-07). "Modelling epidemics with fractional-dose vaccination in response to limited vaccine supply". Journal of Theoretical Biology (in Turanci). 486: 110085. doi:10.1016/j.jtbi.2019.110085. ISSN 0022-5193. PMID 31758966. S2CID 208254350.
|hdl-access=
requires|hdl=
(help) - ↑ 2.0 2.1 Vannice, Kirsten; Wilder-Smith, Annelies; Hombach, Joachim (2018-08-16). "Fractional-Dose Yellow Fever Vaccination — Advancing the Evidence Base". New England Journal of Medicine. 379 (7): 603–605. doi:10.1056/NEJMp1803433. ISSN 0028-4793. PMID 29995585. S2CID 205114579. Cite error: Invalid
<ref>
tag; name ":0" defined multiple times with different content - ↑ 3.0 3.1 Hunziker, Patrick (2021-07-24). "Personalized-dose Covid-19 vaccination in a wave of virus Variants of Concern: Trading individual efficacy for societal benefit". Precision Nanomedicine (in Turanci). 4 (3). doi:10.33218/001c.26101. ISSN 2639-9431. Cite error: Invalid
<ref>
tag; name ":1" defined multiple times with different content - ↑ Schnyder, Jenny L.; De Pijper, Cornelis A.; Garcia Garrido, Hannah M.; Daams, Joost G.; Goorhuis, Abraham; Stijnis, Cornelis; Schaumburg, Frieder; Grobusch, Martin P. (2020-09-01). "Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination - A systematic review and meta-analysis". Travel Medicine and Infectious Disease (in Turanci). 37: 101868. doi:10.1016/j.tmaid.2020.101868. ISSN 1477-8939. PMC 7474844. PMID 32898704.
- ↑ Resik, Sonia; Tejeda, Alina; Sutter, Roland W.; Diaz, Manuel; Sarmiento, Luis; Alemañi, Nilda; Garcia, Gloria; Fonseca, Magilé; Hung, Lai Heng; Kahn, Anna-Lea; Burton, Anthony (2013-01-31). "Priming after a Fractional Dose of Inactivated Poliovirus Vaccine". New England Journal of Medicine. 368 (5): 416–424. doi:10.1056/NEJMoa1202541. ISSN 0028-4793. PMID 23363495.
- ↑ Samfuri:Cite medRxiv
- ↑ World Health Organization (2016-07-20). "Fractional dose yellow fever vaccine as a dose-sparing option for outbreak response". WHO Secretariat Information Paper (in Turanci).
- ↑ "Millions protected in Africa's largest-ever emergency yellow fever vaccination campaign". WHO News Release (in Turanci). 2 September 2016. Retrieved 2022-06-08.
- ↑ Roukens, Anna H.E.; van Halem, Karlijn; de Visser, Adriëtte W.; Visser, Leo G. (2018-11-27). "Long-Term Protection After Fractional-Dose Yellow Fever Vaccination". Annals of Internal Medicine. 169 (11): 761–765. doi:10.7326/m18-1529. ISSN 0003-4819. PMID 30476963. S2CID 53737386.
- ↑ Nelson, Katherine S.; Janssen, Julia M.; Troy, Stephanie B.; Maldonado, Yvonne (2012-01-05). "Intradermal fractional dose inactivated polio vaccine: A review of the literature". Vaccine (in Turanci). 30 (2): 121–125. doi:10.1016/j.vaccine.2011.11.018. ISSN 0264-410X. PMID 22100886.
- ↑ Hunziker, Patrick (2021-07-24). "Personalized-dose Covid-19 vaccination in a wave of virus Variants of Concern: Trading individual efficacy for societal benefit". Precision Nanomedicine (in Turanci). 4 (3): 805–820. doi:10.33218/001c.26101.
- ↑ Wallace, Megan; Oliver, Sara (2021-06-23). "COVID-19 mRNA vaccines in adolescents and young adults: Benefit-risk discussion" (PDF).
- Articles which use infobox templates with no data rows
- Articles using generic infobox
- All articles with unsourced statements
- Articles with unsourced statements from March 2022
- Articles with invalid date parameter in template
- Rigakafi
- Pages with reference errors
- CS1 errors: param-access
- CS1 Turanci-language sources (en)